Biologics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Application, Source, Manufacturing, and Geography

Description

List of Tables

According to our new research study on "Biologics Market Forecast to 2031 - Global Analysis - by Product, Application, Source, Manufacturing, and Geography," the market is anticipated to grow from US$ 469.2 billion in 2023 and is projected to reach US$ 1,793.9 billion by 2031; it is expected to register a CAGR of 18.2% during 2023-2031. Market growth is attributed to increasing cases of chronic diseases and subsequent approvals for several disease-modifying therapies. Evolution of biotechnology industry in developing regions are likely to offer opportunities for the market growth. However, the stringent regulations and high drug development costs hinder the growth of the market.

Biologics are among the most promising avenues in the pharmaceutical industry, offering a unique approach to treating various diseases and medical conditions. The biologics market is constantly growing because pharma and biotechnology companies enormously invest in improving their production facilities. The increasing number of cases and diagnoses of chronic diseases requires the availability of sophisticated diagnostic and treatment drugs, which has boosted the global biologics market. Furthermore, rising demand, higher acceptance of innovative therapies, and increasing clinical trials are expected to drive market growth. However, approving biosimilars is one of the main aspects limiting the biologics market expansion.

North America accounted for a major share of the global biologics market in 2023. The North America biologics market is segmented into the US, Canada, and Mexico. The key factors driving the market growth in this region is the high prevalence of chronic diseases, numerous leading biopharmaceutical companies, favorable reimbursement policies, and significant investments in research and development. According to an article published in JAMA Network, biologics accounted for 37% of total drug spending in the US. The increasing share of prescriptions for biologics and growing investments in developing targeted drugs are contributing to the market growth. Additionally, approvals for several novel biological drugs such as antisense, gene therapy, and RNAi therapeutics are expected to drive market growth further.

Evolution of Biotechnology Industry in Developing Regions to Provide Market Opportunities in Future

In modern biotechnology, antibodies are required in numerous processes, from basic research to innovative medical evaluations. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in antibody-based diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of the biotechnology industry in regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most advantageous destinations for the biotechnology industry. Continuous advancements in the fields of biotechnology, genetics, and cell biology have contributed to identifying the potential of therapeutics for targeted therapies. As the biotechnology industry expands scientists' toolboxes, the combination of basic research, translational studies, and clinical trials will continue to develop, investigate, and test additional compounds, techniques, and therapeutic pathways. Biotechnology is a strategic sector for China. The Made in China 2025 initiative aims to produce high-tech products, including innovative medicines. The plan introduced targets for Chinese pharmaceutical companies to spur biotechnology innovation and increase exports. Furthermore, these Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing evolution of the biotechnology industry in developing regions is expected to create opportunities for the biologics market in the coming years.

Product -Based Insights

Based on product, the biologics market is divided into monoclonal antibodies, vaccines, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023 and is likely to register the highest CAGR during 2023-2031.

Application -Based Insights

The market, based on application, is divided into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest share of the market in 2023 and is anticipated to register the highest CAGR during 2023-2031.

Source -Based Insights

Based on source, the market is segmented into mammalian and microbial. The microbial segment held a larger market share in 2023. The mammalian is estimated to record a faster CAGR during 2023-2031. Mammalian expression systems are mainly used to develop recombinant proteins and vaccines based on viral vectors. The most frequently used mammalian cell lines are CHO and HEK. Products such as Perjeta (pertuzumab), Adcetris (brentuximab vedotin), Kadycla (trastuzumab emtansine), Shingrix (zoster vaccine), and Aimovig (erenumab) are among the products manufactured in mammalian expression systems.

Biologics Market: Competitive Landscape and Key Developments

AbbVie Inc.; Pfizer Inc.; Samsung Biologics; ADMA Biologics, Inc.; WuXi Biologics; Catalent, Inc; AGC Biologics; Crescendo Biologics Limited; Zumutor Biologics INC; Theriva Biologics; AstraZeneca; Amgen Inc.; Avecia Biologics; and Quality Assistance s.a. are among the key companies operating in the biologics market.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the biologics market report.

Product Code: TIPRE00002765

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Biologics Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Biologics Market - Key Market Dynamics

5.1 Biologics Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increasing Prevalence of Chronic Diseases
- 5.2.2 Preference for Outsourcing Manufacturing Operations
5.3 Market Restraints
- 5.3.1 High Cost of Biologics
5.4 Market Opportunities
- 5.4.1 Evolution of Biotechnology in Developing Regions
5.5 Future Trends
- 5.5.1 Strategic Initiatives by Companies
5.6 Impact of Drivers and Restraints:

6. Biologics Market - Global Market Analysis

6.1 Biologics Market Revenue (US$ Million), 2021-2031
6.2 Biologics Market Forecast Analysis

7. Biologics Market Analysis - by Product

7.1 Monoclonal Antibodies
- 7.1.1 Overview
- 7.1.2 Monoclonal Antibodies: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Vaccine
- 7.2.1 Overview
- 7.2.2 Vaccine: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Recombinant Hormones/Proteins
- 7.3.1 Overview
- 7.3.2 Recombinant Hormones/Proteins: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Cell and Gene Therapy
- 7.4.1 Overview
- 7.4.2 Cell and Gene Therapy: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

8. Biologics Market Analysis - by Application

8.1 Cancer
- 8.1.1 Overview
- 8.1.2 Cancer: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
- 8.2.1 Overview
- 8.2.2 Infectious Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Autoimmune Diseases
- 8.3.1 Overview
- 8.3.2 Autoimmune Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

9. Biologics Market Analysis - by Source

9.1 Mammalian
- 9.1.1 Overview
- 9.1.2 Mammalian: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Microbial
- 9.2.1 Overview
- 9.2.2 Microbial: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

10. Biologics Market Analysis - by Manufacturing

10.1 Outsourced
- 10.1.1 Overview
- 10.1.2 Outsourced: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
10.2 In-house
- 10.2.1 Overview
- 10.2.2 In-house: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

11. Biologics Market - Geographical Analysis

11.1 Overview
11.2 North America
- 11.2.1 North America Biologics Market Overview
- 11.2.2 North America: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.3 North America: Biologics Market Breakdown, by Product
  - 11.2.3.1 North America: Biologics Market - Revenue and Forecast Analysis - by Product
- 11.2.4 North America: Biologics Market Breakdown, by Application
  - 11.2.4.1 North America: Biologics Market - Revenue and Forecast Analysis - by Application
- 11.2.5 North America: Biologics Market Breakdown, by Source
  - 11.2.5.1 North America: Biologics Market - Revenue and Forecast Analysis - by Source
- 11.2.6 North America: Biologics Market Breakdown, by Manufacturing
  - 11.2.6.1 North America: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
- 11.2.7 North America: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.2.7.1 North America: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.2.7.2 United States: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.7.2.1 United States: Biologics Market Breakdown, by Product
    - 11.2.7.2.2 United States: Biologics Market Breakdown, by Application
    - 11.2.7.2.3 United States: Biologics Market Breakdown, by Source
    - 11.2.7.2.4 United States: Biologics Market Breakdown, by Manufacturing
  - 11.2.7.3 Canada: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.7.3.1 Canada: Biologics Market Breakdown, by Product
    - 11.2.7.3.2 Canada: Biologics Market Breakdown, by Application
    - 11.2.7.3.3 Canada: Biologics Market Breakdown, by Source
    - 11.2.7.3.4 Canada: Biologics Market Breakdown, by Manufacturing
  - 11.2.7.4 Mexico: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.7.4.1 Mexico: Biologics Market Breakdown, by Product
    - 11.2.7.4.2 Mexico: Biologics Market Breakdown, by Application
    - 11.2.7.4.3 Mexico: Biologics Market Breakdown, by Source
    - 11.2.7.4.4 Mexico: Biologics Market Breakdown, by Manufacturing
11.3 Europe
- 11.3.1 Europe Biologics Market Overview
- 11.3.2 Europe: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
- 11.3.3 Europe: Biologics Market Breakdown, by Product
  - 11.3.3.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Product
- 11.3.4 Europe: Biologics Market Breakdown, by Application
  - 11.3.4.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Application
- 11.3.5 Europe: Biologics Market Breakdown, by Source
  - 11.3.5.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Source
- 11.3.6 Europe: Biologics Market Breakdown, by Manufacturing
  - 11.3.6.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
- 11.3.7 Europe: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.3.7.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.3.7.2 Germany: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.2.1 Germany: Biologics Market Breakdown, by Product
    - 11.3.7.2.2 Germany: Biologics Market Breakdown, by Application
    - 11.3.7.2.3 Germany: Biologics Market Breakdown, by Source
    - 11.3.7.2.4 Germany: Biologics Market Breakdown, by Manufacturing
  - 11.3.7.3 United Kingdom: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.3.1 United Kingdom: Biologics Market Breakdown, by Product
    - 11.3.7.3.2 United Kingdom: Biologics Market Breakdown, by Application
    - 11.3.7.3.3 United Kingdom: Biologics Market Breakdown, by Source
    - 11.3.7.3.4 United Kingdom: Biologics Market Breakdown, by Manufacturing
  - 11.3.7.4 Italy: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.4.1 Italy: Biologics Market Breakdown, by Product
    - 11.3.7.4.2 Italy: Biologics Market Breakdown, by Application
    - 11.3.7.4.3 Italy: Biologics Market Breakdown, by Source
    - 11.3.7.4.4 Italy: Biologics Market Breakdown, by Manufacturing
  - 11.3.7.5 France: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.5.1 France: Biologics Market Breakdown, by Product
    - 11.3.7.5.2 France: Biologics Market Breakdown, by Application
    - 11.3.7.5.3 France: Biologics Market Breakdown, by Source
    - 11.3.7.5.4 France: Biologics Market Breakdown, by Manufacturing
  - 11.3.7.6 Spain: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.6.1 Spain: Biologics Market Breakdown, by Product
    - 11.3.7.6.2 Spain: Biologics Market Breakdown, by Application
    - 11.3.7.6.3 Spain: Biologics Market Breakdown, by Source
    - 11.3.7.6.4 Spain: Biologics Market Breakdown, by Manufacturing
  - 11.3.7.7 Rest of Europe: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.7.1 Rest of Europe: Biologics Market Breakdown, by Product
    - 11.3.7.7.2 Rest of Europe: Biologics Market Breakdown, by Application
    - 11.3.7.7.3 Rest of Europe: Biologics Market Breakdown, by Source
    - 11.3.7.7.4 Rest of Europe: Biologics Market Breakdown, by Manufacturing
11.4 Asia Pacific
- 11.4.1 Asia Pacific Biologics Market Overview
- 11.4.2 Asia Pacific: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
- 11.4.3 Asia Pacific: Biologics Market Breakdown, by Product
  - 11.4.3.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Product
- 11.4.4 Asia Pacific: Biologics Market Breakdown, by Application
  - 11.4.4.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Application
- 11.4.5 Asia Pacific: Biologics Market Breakdown, by Source
  - 11.4.5.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Source
- 11.4.6 Asia Pacific: Biologics Market Breakdown, by Manufacturing
  - 11.4.6.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
- 11.4.7 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.4.7.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.4.7.2 China: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.2.1 China: Biologics Market Breakdown, by Product
    - 11.4.7.2.2 China: Biologics Market Breakdown, by Application
    - 11.4.7.2.3 China: Biologics Market Breakdown, by Source
    - 11.4.7.2.4 China: Biologics Market Breakdown, by Manufacturing
  - 11.4.7.3 India: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.3.1 India: Biologics Market Breakdown, by Product
    - 11.4.7.3.2 India: Biologics Market Breakdown, by Application
    - 11.4.7.3.3 India: Biologics Market Breakdown, by Source
    - 11.4.7.3.4 India: Biologics Market Breakdown, by Manufacturing
  - 11.4.7.4 Japan: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.4.1 Japan: Biologics Market Breakdown, by Product
    - 11.4.7.4.2 Japan: Biologics Market Breakdown, by Application
    - 11.4.7.4.3 Japan: Biologics Market Breakdown, by Source
    - 11.4.7.4.4 Japan: Biologics Market Breakdown, by Manufacturing
  - 11.4.7.5 South Korea: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.5.1 South Korea: Biologics Market Breakdown, by Product
    - 11.4.7.5.2 South Korea: Biologics Market Breakdown, by Application
    - 11.4.7.5.3 South Korea: Biologics Market Breakdown, by Source
    - 11.4.7.5.4 South Korea: Biologics Market Breakdown, by Manufacturing
  - 11.4.7.6 Australia: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.6.1 Australia: Biologics Market Breakdown, by Product
    - 11.4.7.6.2 Australia: Biologics Market Breakdown, by Application
    - 11.4.7.6.3 Australia: Biologics Market Breakdown, by Source
    - 11.4.7.6.4 Australia: Biologics Market Breakdown, by Manufacturing
  - 11.4.7.7 Rest of APAC: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.7.1 Rest of APAC: Biologics Market Breakdown, by Product
    - 11.4.7.7.2 Rest of APAC: Biologics Market Breakdown, by Application
    - 11.4.7.7.3 Rest of APAC: Biologics Market Breakdown, by Source
    - 11.4.7.7.4 Rest of APAC: Biologics Market Breakdown, by Manufacturing
11.5 Middle East and Africa
- 11.5.1 Middle East and Africa Biologics Market Overview
- 11.5.2 Middle East and Africa: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
- 11.5.3 Middle East and Africa: Biologics Market Breakdown, by Product
  - 11.5.3.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Product
- 11.5.4 Middle East and Africa: Biologics Market Breakdown, by Application
  - 11.5.4.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Application
- 11.5.5 Middle East and Africa: Biologics Market Breakdown, by Source
  - 11.5.5.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Source
- 11.5.6 Middle East and Africa: Biologics Market Breakdown, by Manufacturing
  - 11.5.6.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
- 11.5.7 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.5.7.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.5.7.2 South Africa: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.2.1 South Africa: Biologics Market Breakdown, by Product
    - 11.5.7.2.2 South Africa: Biologics Market Breakdown, by Application
    - 11.5.7.2.3 South Africa: Biologics Market Breakdown, by Source
    - 11.5.7.2.4 South Africa: Biologics Market Breakdown, by Manufacturing
  - 11.5.7.3 Saudi Arabia: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.3.1 Saudi Arabia: Biologics Market Breakdown, by Product
    - 11.5.7.3.2 Saudi Arabia: Biologics Market Breakdown, by Application
    - 11.5.7.3.3 Saudi Arabia: Biologics Market Breakdown, by Source
    - 11.5.7.3.4 Saudi Arabia: Biologics Market Breakdown, by Manufacturing
  - 11.5.7.4 United Arab Emirates: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.4.1 United Arab Emirates: Biologics Market Breakdown, by Product
    - 11.5.7.4.2 United Arab Emirates: Biologics Market Breakdown, by Application
    - 11.5.7.4.3 United Arab Emirates: Biologics Market Breakdown, by Source
    - 11.5.7.4.4 United Arab Emirates: Biologics Market Breakdown, by Manufacturing
  - 11.5.7.5 Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.5.1 Rest of Middle East and Africa: Biologics Market Breakdown, by Product
    - 11.5.7.5.2 Rest of Middle East and Africa: Biologics Market Breakdown, by Application
    - 11.5.7.5.3 Rest of Middle East and Africa: Biologics Market Breakdown, by Source
    - 11.5.7.5.4 Rest of Middle East and Africa: Biologics Market Breakdown, by Manufacturing
11.6 South and Central America
- 11.6.1 South and Central America Biologics Market Overview
- 11.6.2 South and Central America: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
- 11.6.3 South and Central America: Biologics Market Breakdown, by Product
  - 11.6.3.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Product
- 11.6.4 South and Central America: Biologics Market Breakdown, by Application
  - 11.6.4.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Application
- 11.6.5 South and Central America: Biologics Market Breakdown, by Source
  - 11.6.5.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Source
- 11.6.6 South and Central America: Biologics Market Breakdown, by Manufacturing
  - 11.6.6.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
- 11.6.7 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.6.7.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Country
  - 11.6.7.2 Brazil: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.6.7.2.1 Brazil: Biologics Market Breakdown, by Product
    - 11.6.7.2.2 Brazil: Biologics Market Breakdown, by Application
    - 11.6.7.2.3 Brazil: Biologics Market Breakdown, by Source
    - 11.6.7.2.4 Brazil: Biologics Market Breakdown, by Manufacturing
  - 11.6.7.3 Argentina: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.6.7.3.1 Argentina: Biologics Market Breakdown, by Product
    - 11.6.7.3.2 Argentina: Biologics Market Breakdown, by Application
    - 11.6.7.3.3 Argentina: Biologics Market Breakdown, by Source
    - 11.6.7.3.4 Argentina: Biologics Market Breakdown, by Manufacturing
  - 11.6.7.4 Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.6.7.4.1 Rest of South and Central America: Biologics Market Breakdown, by Product
    - 11.6.7.4.2 Rest of South and Central America: Biologics Market Breakdown, by Application
    - 11.6.7.4.3 Rest of South and Central America: Biologics Market Breakdown, by Source
    - 11.6.7.4.4 Rest of South and Central America: Biologics Market Breakdown, by Manufacturing

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in Biologics Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 AbbVie Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Pfizer Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Samsung Biologics Co Ltd
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 WuXi Biologics Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Catalent Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AGC Biologics AS
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 AstraZeneca Plc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Amgen Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Nitto Avecia
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Quality Assistance s.a.
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments

14. Appendix

14.1 About The Insight Partners